No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDNA240719C15000
- 2.75
- +1.74+172.28%
15min DelayClose Jul 16 15:59 ET
2.75High2.75Low
2.75Open1.01Pre Close1 Volume59 Open Interest15.00Strike Price275.00Turnover311.83%IV-4.42%PremiumJul 19, 2024Expiry Date3.57Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8227Delta0.0517Gamma4.50Leverage Ratio-0.2467Theta0.0008Rho3.70Eff Leverage0.0042Vega
Intraday
- 5D
- Daily
News
CareDx to Report Second Quarter 2024 Financial Results
Nephron Initiates CareDx at Hold Rating With $15 Price Target
07:57 AM EDT, 07/10/2024 (MT Newswires) -- Nephron Initiates CareDx at Hold Rating With $15 Price
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Craig-Hallum analyst William Bonello maintains $CareDx(CDNA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 75.0% and a total average return of 39.3% over the past
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in
Express News | CareDx Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $17 Vs $12
Decoding 6 Analyst Evaluations For CareDx
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months.The table below summarizes their recent ratings, s
Comments
Investors may believe CareDx's strong revenue growth is not imminent, leading to a low P/S ratio. Expected future revenue decline could further decrease the P/S ratio, making a significant stock price rise unlikely.
Little Excitement Around CareDx, Inc's (NASDAQ:CDNA) Revenues As Shares Take 28% PoundingDespite a strong price move, CareDx's P/S ratio still trails the industry. The low P/S is due to the forecast for sliding revenue. Without significant change, drastic rise in the stock is unlikely.
$CareDx(CDNA.US$ 4.80 missed and ran 📈👀
$CareDx(CDNA.US$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
Read more